Taiwan will amend its National Health Insurance Drug Reimbursement Guidelines (NHIDRG) to encourage country's pharmaceutical companies to produce more medicines within the country. The announcement comes amid possible price fluctuations caused by exchange rate changes or increased costs resulting from the new US tariffs.